Construction of an algorithm based on oncosis‐related LncRNAs comprising the molecular subtypes and a risk assessment model in lung adenocarcinoma. Issue 6 (27th April 2022)

• Record Type: Journal Article
• Authors: Chen, Hang; Zhou, Chongchang; Hu, Zeyang; Sang, Menglu; Ni, Saiqi; Wu, Jiacheng; Pan, Qiaoling; Tong, Jingtao; Liu, Kaitai; Li, Ni; Zhu, Linwen; Xu, Guodong
• Is Part Of: Journal of clinical laboratory analysis. Volume 36:Issue 6(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-27
• Subjects: cluster analysis -- lung adenocarcinoma -- oncosis‐related lncRNAs -- prognostic signature -- tumor immunity; Diagnosis, Laboratory -- Periodicals; Medical laboratory technology -- Periodicals; 616
• DOI: 10.1002/jcla.24461
• Languages: English
• ISSNs: 0887-8013

Abstract

Abstract: Background: As an important non‐apoptotic cell death method, oncosis has been reported to be closely associated with tumors in recent years. However, few research reported the relationship between oncosis and lung cancer. Methods: In this study, we established an oncosis‐based algorithm comprised of cluster grouping and a risk assessment model to predict the survival outcomes and related tumor immunity of patients with lung adenocarcinomas (LUAD). We selected 11 oncosis‐related lncRNAs associated with the prognosis (CARD8‐AS1, LINC00941, LINC01137, LINC01116, AC010980.2, LINC00324, AL365203.2, AL606489.1, AC004687.1, HLA‐DQB1‐AS1, and AL590226.1) to divide the LUAD patients into different clusters and different risk groups. Compared with patients in clsuter1, patients in cluster2 had a survival advantage and had a relatively more active tumor immunity. Subsequently, we constructed a risk assessment model to distinguish between patients into different risk groups, in which low‐risk patients tend to have a better prognosis. GO enrichment analysis revealed that the risk assessment model was closely related to immune activities. In addition, low‐risk patients tended to have a higher content of immune cells and stromal cells in tumor microenvironment, higher expression of PD‐1, CTLA‐4, HAVCR2, and were more sensitive to immune checkpoint inhibitors (ICIs), including PD‐1/CTLA‐4 inhibitors. The risk score had a significantly positive correlation with tumor mutation burden (TMB). The survival curve of the novel oncosis‐based algorithm suggested that low‐risk patients in cluster2 have the most obvious survival advantage. Conclusion: The novel oncosis‐based algorithm investigated the prognosis and the related tumor immunity of patients with LUAD, which could provide theoretical support for customized individual treatment for LUAD patients. Abstract : The flowchart for constructing a novel oncosis‐based algorithm and its implication.